Prescribing information

 

       

ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) provides comprehensive bronchodilation and on-target inflammatory action1

IMage of lungs showing Enerzair breezhaler providing comprehensive bronchodilation and on-target inflammatory action

Controlling the inflammation is the principal objective of asthma therapy. A comprehensive bronchodilation supports the ICS to reach deep into the lungs, where the inflammation resides, for an on-target inflammation control.

Indication: ENERZAIR BREEZHALER is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.1

ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist.

References

  1. ENERZAIR BREEZHALER Summary of Product Characteristics.
  2. Bousquet J. Int J Clin Pract 2009;63(5):806–819.
  3. Yang D et al. Asian Pac J Allergy Immunol 2013;31(1):26–35.
  4. Blais C et al. Respir Res 2017;18:146.
  5. Beeh K et al. Eur Respir J 2007;29:871–878.
  6. Hansel T et al. CHEST 2005;128:1974–1979.
ENE20-C003 November 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]